5 Key Takeaways

• 1

  Japan has granted conditional approval for two iPSC-derived therapies, marking a global regulatory first for this technology.

• 2

  ReHeart is an iPSC-derived cardiomyocyte sheet for severe heart failure, aimed at patients with no conventional treatment options.

• 3

  Amchepry is a dopaminergic neural progenitor cell therapy for Parkinson’s disease, showing promise in a small clinical trial.

• 4

  The approvals allow for commercialization while additional safety and efficacy data are collected post-approval.

• 5

  Both therapies have limited clinical evidence, having been tested in small early-stage trials with fewer than ten patients.